Summary
This multiomic study integrated genomic, transcriptomic and proteomic data from end-stage high-grade serous ovarian cancer samples to characterise molecular subtypes stratified by homologous recombination deficiency status. The analysis, as suggested by the authorship and Nature Genetics publication venue, identifies distinct biological pathways and molecular signatures associated with HR deficiency that may support treatment stratification and prognosis in advanced ovarian cancer. The work provides a comprehensive molecular taxonomy of this cancer subtype.
UK applicability
This molecular characterisation may inform treatment selection and prognostic assessment in UK ovarian cancer care, particularly for patients with HR-deficient tumours. The findings could support stratification in clinical trials and precision oncology approaches adopted by NHS cancer centres.
Key measures
Genomic variants, gene expression profiles, protein abundance, homologous recombination deficiency status classification
Outcomes reported
The study characterised molecular subtypes and biological pathways in end-stage high-grade serous ovarian cancer samples using integrated genomic, transcriptomic and proteomic analysis stratified by homologous recombination deficiency status. The multiomic approach identified distinct molecular signatures associated with HR deficiency that may inform treatment stratification and prognostic assessment.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.